• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

    75.92 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 25
    Open 75.92
    Bid (Size) 73.00 (100)
    Ask (Size) 77.15 (100)
    Prev. Close 75.92
    Today's Range 75.92 - 75.92
    52wk Range 24.00 - 123.75
    Shares Outstanding 11,834,361
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗
    Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases. 
    Via The Motley Fool
    Topics Regulatory Compliance Stocks

    Performance

    YTD
    -9.0%
    -9.0%
    1 Month
    +28.3%
    +28.3%
    3 Month
    -15.3%
    -15.3%
    6 Month
    -15.9%
    -15.9%
    1 Year
    +211.7%
    +211.7%

    More News

    Read More
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance
    News headline image
    Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Bright Minds Biosciences Announces Closing of US$175 Million Public Offering
    From Bright Minds Biosciences
    Via GlobeNewswire
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Tuesday's session. ↗
    Via Chartmill
    News headline image
    Why Did DRUG Stock Rocket 51% Today? ↗
    Via Stocktwits
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Why Bright Minds Biosciences Stock Topped the Market on Monday ↗
    Via The Motley Fool
    News headline image
    Large Patient Population Is Key Driver For Bright Minds' Growth ↗
    Via Benzinga
    News headline image
    Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗
    Via Benzinga
    News headline image
    Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Biotechs on the Brink: 2 Stocks With Huge Potential
    Via MarketBeat
    News headline image
    This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗
    Via The Motley Fool
    News headline image
    Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗
    Via Benzinga
    Topics Government
    News headline image
    What's Going On With Bright Minds Biosciences Stock? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
    From Bright Minds Biosciences
    Via GlobeNewswire
    News headline image
    MarketBeat Week in Review – 10/14 - 10/18
    Via MarketBeat
    Topics Artificial Intelligence Economy

    Frequently Asked Questions

    Is Bright Minds Biosciences Inc. - common stock publicly traded?
    Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.
    What exchange does Bright Minds Biosciences Inc. - common stock trade on?
    Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?
    The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market
    What is the current price of Bright Minds Biosciences Inc. - common stock?
    The current price of Bright Minds Biosciences Inc. - common stock is 75.92
    When was Bright Minds Biosciences Inc. - common stock last traded?
    The last trade of Bright Minds Biosciences Inc. - common stock was at 07/15/26 04:00 PM ET
    What is the market capitalization of Bright Minds Biosciences Inc. - common stock?
    The market capitalization of Bright Minds Biosciences Inc. - common stock is 898.46M
    How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?
    Bright Minds Biosciences Inc. - common stock has 898M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.